Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;9(12):1251-7.
doi: 10.1080/14622200701705027.

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials

Sean P David  1 , David R Strong, Marcus R Munafò, Richard A Brown, Elizabeth E Lloyd-Richardson, Paul E Wileyto, Eden A Evins, Peter G Shields, Caryn Lerman, Raymond Niaura
Affiliations

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials

Sean P David et al. Nicotine Tob Res. 2007 Dec.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Nicotine Tob Res. 2018 May 3;20(6):784. doi: 10.1093/ntr/ntx173. Nicotine Tob Res. 2018. PMID: 29059421 No abstract available.

Abstract

We analyzed pooled data from two comparable randomized placebo-controlled clinical trials of bupropion pharmacotherapy for smoking cessation for which data on DRD2 Taq1A genotype were available. A total of 722 smokers across the two trials were randomized to 10 weeks of sustained-release bupropion hydrochloride or placebo. General estimating equation analysis demonstrated a significant gene x drug interaction (B = 0.87, SE = 0.34, p = .009). Smokers with the A2/A2 genotype using bupropion were more than three times as likely, relative to placebo, to be abstinent at end of treatment (35.2% vs. 15.1%; OR = 3.25, 95% CI 2.00-5.28) and at 6 months of follow-up (26.7% vs. 12.2%; OR = 2.81, 95% CI 1.66-4.77), which was attenuated by 12 months (16.3% vs. 10.7%; OR = 1.70, 95% CI 0.95-3.05). We found no significant benefit of bupropion relative to placebo on smoking cessation outcomes at any time point in participants with A1/A1 or A1/A2 genotypes. These data suggest that bupropion may be effective for smoking cessation only in a subgroup of smokers with the DRD2 Taq1 A2/A2 genotype.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Smoking cessation outcomes by treatment condition and DRD2 Taq1A genotype. Rate of biochemically verified 7-day point-prevalence abstinence at end of treatment and at 6- and 12-month follow-up assessments grouped by DRD2 Taq1 genotype and treatment condition (A1/A1 or A1/A2 on placebo: solid; A1/A1 or A1/A2 on bupropion: dashed; A2/A2 on placebo (PBO): dotted; A2/A2 on bupropion (BUP): dotted and dashed).
See this image and copyright information in PMC

References

    1. American Psychiatric Assocation. Diagnostics and statistical manual of mental disorders. 4. Washington, DC: Author; 1994.
    1. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F. Bupropion: A review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry. 1995;56:395–401. - PubMed
    1. Balfour DJ. Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Current Drug Targets Central Nervous System and Neurological Disorders. 2002;1:413–421. - PubMed
    1. Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB. Allelic association of human dopamine D2 receptor gene in alcoholism. The Journal of the American Medical Association. 1990;263:2055–2060. - PubMed
    1. Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM, Abrams D, Miller IW. Bupropion and cognitive behavioral treatment for depression in smoking cessation. Nicotine & Tobacco Research. 2007;9:721–730. - PMC - PubMed

Publication types

MeSH terms